JAN 07, 2019 11:36 AM PST

Researchers Develop an Experimental Therapy for Triple-negative Breast Cancer

WRITTEN BY: Carmen Leitch

Between twelve and seventeen percent of all breast cancer cases are triple-negative, a highly aggressive type. It lacks three common cancer therapeutic targets: human epidermal growth factor receptor 2 (HER2) and the progesterone (PR) and estrogen receptors (ER). Now researchers have created an experimental therapy for this deadly cancer, which was able to slow the metastasis of triple-negative breast cancer in a mouse model. The therapeutic protein, Tinagl1, can block two main pathways that breast cancer cells use to grow and metastasize, and is based on a natural protein. The findings were reported in Cancer Cell.

Treatment with recombinant Tinagl1 protein significantly suppressed lung metastasis, as shown by the blue arrows in mice with (right) or without (left) Tinagl1 treatment. / Credit: Image courtesy of Yibin Kang et al., Princeton University

"People have tried to block the spread of this form of cancer, but attempts so far have failed because if you try one approach, the cancer cells compensate by finding a way to escape," noted the senior author of the work Yibin Kang, the Warner-Lambert/Parke-Davis Professor of Molecular Biology at Princeton University and associate director for consortium research at the Rutgers Cancer Institute of New Jersey. "With this new approach, the treatment blocks both pathways at the same time. It is like having one stone that kills two birds."

There aren't many treatment options for patients with triple-negative breast cancer; there is a high chance of relapse, and the prognosis is poor. This cancer can also become resistant to treatment. This work shows that there may be an option for these individuals one day.

The scientists determined that Tinagl1 was able to stop the action of a protein called epidermal growth factor receptor gene (EGFR), which can promote tumor growth; if the gene that encodes for EGFR contains mutations, its activity increases, which fuels the growth of tumors and encourages cells to break off and migrate to other parts of the body. Therapeutics that target EGFR have not been particularly effective, potentially because cancer cells can use alternative pathways when EGFR is down. Tinagl1 was able to inhibit EGFR.

Image of human breast cancer conditionally reprogrammed cells in culture. Fluorescence red color represents MHC-I, and nuclei are shown in blue. / Credit: National Cancer Institute / Georgetown Lombardi Comprehensive Cancer Center / Ewa Krawczyk
 

The other pathway that was impacted by the therapeutic involves molecules called integrins, which help control cell movement and adhesion, and the shift to malignancy. Tinagl1 seems to disrupt integrin signaling by acting on another protein, focal adhesion kinase (FAK), which also functions in cell growth and migration as well as survival. These pathways are physiologically connected, with redundancy and compensation that enables cancer to evade treatment and grow aggressively, noted the scientists. The team found that both were inhibited by the experimental therapeutic.

Over 800 samples of human breast tumors were assessed for this work, which showed that tumor samples with lower Tinagl1 gene expression levels tended to come from advanced cancers and patients with shorter survival times. When tumors had high Tinagl1 expression levels, patients were more likely to have a good prognosis. In the triple-negative breast cancer samples, those differences were most pronounced.

After exposing mice with mammary tumors to the Tinagl1 protein for seven weeks, the researchers found that the growth of the primary tumors in the mice was inhibited, and there was less metastasis to the lungs. That treatment had an impact even when the metastasis had already started.

The researchers also investigated whether the Tinagl1 gene helps shield against the growth and spread of tumors by engineering tumor cells with high Tinagl1 gene expression. In mouse cancer cells, high expression levels reduced cancer growth and metastasis. However, mouse models have been cured of cancer before. This research does not necessarily mean this therapy will be effective in humans. Much more follow-up work will be needed.  

In the video above, Kang discusses breast cancer and metastasis.


Sources: AAAS/Eurekalert! via Princeton University, Cancer Cell

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
JAN 07, 2019
Health & Medicine
JAN 07, 2019
Associations Between Secondhand Smoke Exposure and the Development of All Cancers
  Researchers in the 1930s, 1940s, and 1950s began to amass evidence of the adverse effects of secondhand smoke; In 1957, Surgeon General Leroy Burney...
JAN 05, 2019
Videos
JAN 05, 2019
Photorespiration Shortcut Boosts Crop Yield
Most crops on earth don't photosynthesize efficiently; they sometimes use a wasteful cellular pathway called photorespiration....
JAN 14, 2019
Cell & Molecular Biology
JAN 14, 2019
Microscopy Advances Enable the Visualization of Cortical Neurons in Live Mice
Scientists will be able to get a better look at cells in the brain after three-photon microscopy was improved....
JAN 18, 2019
Genetics & Genomics
JAN 18, 2019
Insight Into the Molecular Basis of Obesity
Obesity is a major health problem around the world, impacting adults and an estimated 41 million children....
JAN 29, 2019
Genetics & Genomics
JAN 29, 2019
Heavy Drinking may Have a Lasting Epigenetic Effect
Researchers have found that alcohol may be exerting an epigenetic effect on heavy or binge drinkers....
FEB 10, 2019
Genetics & Genomics
FEB 10, 2019
Researchers Sequence 100 New Gut Microbes, Advancing Microbiome Research
We all carry around a massive community of microbes in our gastrointestinal tracts, which help us digest food and absorb nutrients....
Loading Comments...